Kidney Cancer

More than half of patients with metastatic clear cell renal cell carcinoma treated with a combination of lenvatinib and pembrolizumab responded to treatment at week 24, according to interim results of a phase I/II study presented at the 2017 ESMO Congress.

African American patients with localized renal cell carcinoma who underwent robotic partial nephrectomy were at an increased risk for positive surgical margins compared with white patients.

This video reviews the various treatment options for metastatic renal cell carcinoma in the second-line setting, including considerations for different toxicity profiles.

This video reviews the first-line treatment of metastatic renal cell carcinoma, including for those patients who are ineligible for interleukin-2.

Patients with metastatic renal cell carcinoma had durable responses and manageable safety when treated with the combination of nivolumab and ipilimumab.

A phase II study has shown that savolitinib is active in a subgroup of patients with papillary renal cell carcinoma with gene amplification or mutations in the MET pathway.

Lack of participation in any regular recreational physical activity was associated with a significantly increased risk for both bladder and renal cancers.

This video examines a pilot trial that tested stereotactic body radiotherapy plus nephrectomy in patients with renal cell carcinoma.

Epacadostat plus pembrolizumab yielded “encouraging response outcomes” among patients with 0 or 1 prior lines of therapy for advanced renal cell carcinoma.

Analysis from a phase III trial confirmed the prognostic value of a 16-gene recurrence score in patients with high-risk renal cell carcinoma undergoing adjuvant sunitinib therapy.

Pazopanib 600 mg daily as adjuvant therapy did not prolong disease-free survival for patients with locally advanced renal cell carcinoma.

This video reviews second-line data from the IMmotion150 trial, which initially studied atezolizumab with or without bevacizumab vs sunitinib in untreated metastatic renal cell carcinoma patients.

Liver toxicity precludes development of pembrolizumab plus pazopanib immunotherapy for patients with advanced renal cell carcinoma.

Plasma levels of HGF, BAP1 and PBRM1 gene mutation status, and angiogenesis gene expression are promising predictive biomarkers for survival in RCC patients.

Despite high rates of toxicity, a first-line tyrosine kinase inhibitor/immunotherapy combination exhibits promising antitumor activity in metastatic renal cell carcinoma.

Individualizing first-line sunitinib was associated with improved response and survival times among patients with metastatic renal cell carcinoma.

The use of nephron-sparing surgery to treat stage I renal tumors increased between 2009 to 2013 in Australia, showing increased compliance with international guidelines.

A subset of patients with advanced renal cell carcinoma experienced a reduction in tumor size after undergoing postprogression treatment with nivolumab.

From 1983 to 2007, the incidence of renal-malignancy end-stage renal disease has greatly increased, according to the results of a study.

BMI was inversely correlated with serum adiponectin levels in RCC, and low BMI and high adiponectin might be associated with disease aggressiveness and survival in patients with the disease.

Updated results of the ASSURE trial showed that adjuvant sunitinib or sorafenib did not improve disease-free survival among high-risk patients with renal cell carcinoma.

Using the HDAC inhibitor vorinostat plus the VEGF inhibitor bevacizumab resulted in clinical activity in patients with clear cell renal cell carcinoma.

Active surveillance prior to initiating targeted therapy might benefit patients with metastatic renal cell carcinoma, since it delays therapy and toxicities.

Computer-assisted tumor objective response evaluations for patients with metastatic renal cell carcinoma can save time and reduce errors.

Suspicious pathology from kidney tumors was significantly associated with testing positive for fumarate hydratase mutations, which may aid in the early diagnosis of hereditary leiomyomatosis and renal cell carcinoma.

Immunotherapy offers durable responses lasting more than 6 months after treatment discontinuation for some patients with metastatic renal cell carcinoma.

Antibiotics administered less than a month before initiation of immunotherapies for patients with advanced kidney cancer might impair tumor control, according to a retrospective analysis.

Breaks from active sunitinib treatment for patients with treatment-naive metastatic renal cell carcinoma may be possible without effecting clinical efficacy.

A study has shown a link between metabolic toxicities and the efficacy of mTOR inhibitors for the treatment of metastatic renal cell carcinoma.

An early study looking at the combination of the ALK1 inhibitor dalantercept plus axitinib showed clinical activity in patients with advanced renal cell carcinoma.